MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2016 International Congress

    Automated Telehealth Diagnostics for Remote Parkinson Monitoring

    D.A. Heldman, D.A. Harris, T. Felong, B. Goldberg, J.P. Giuffrida, E.R. Dorsey, M.A. Burack (Cleveland, OH, USA)

    Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…
  • 2016 International Congress

    Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

    G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

    Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…
  • 2016 International Congress

    FBOX07 mutation with juvenile parkinsonism and behavioral disorders

    M. Kuzu, F.N. Durmaz, Ç. Ulukan, H. Kaymakçalan, A.O. Çaglayan, C. Akbostanci (Ankara, Turkey)

    Objective: FBX07 (PARK15) mutations cause juvenile parkinsonism with autosomal ressesive inheritance. Juvenile parkinsonism, pyramidal tract signs and atypical symptoms such as dystonia, chorea, behavioral disturbances,…
  • 2016 International Congress

    Self-perception of daily performance in relation to motor performance in advanced Parkinson’s disease – Case studies

    J. Jansa, B. Piks, D. Flisar, M. Gregoric Kramberger, Z. Pirtosek (Ljubljana, Slovenia)

    Objective: To evaluate Parkinson's disease (PD) patients' perception of their performance of daily living (ADL) in their “ON” and “OF” stages and relate them to…
  • 2016 International Congress

    Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

    M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

    Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…
  • 2016 International Congress

    A web resource on levodopa-induced dyskinesia (LID) genetics

    M. Falla, H. Blankenburg, P. Gruber, I. Pichler, C. Schwienbacher, A. Hicks, F. Domingues, P.P. Pramstaller (Bolzano/Bozen, Italy)

    Objective: Establish a web resource summarizing literature-based genetic information on levodopa-induced dyskinesia in an easily accessible and consistent way. Background: Levodopa induced dyskinesia (LID) is…
  • 2016 International Congress

    Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

    J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

    Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…
  • 2016 International Congress

    AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

    L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

    Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…
  • 2016 International Congress

    How many and which kind of Parkinson’s disease patients need deep brain stimulation surgery? An evaluation based on clinical observation of patients with disease history of 15th year or more

    H. Shibayama, T. Fukumoto, M. Tomura, K. Tokumoto, H. Yano, K. Tajima, F. Mitobe, F. Katada, S. Sato, T. Fukutake (Kamogawa City, Chiba, Japan)

    Objective: To grasp real demand of deep brain stimulation (DBS) surgery in a substantial Parkinson's disease (PD) population. Background: DBS surgery has become frequently performed…
  • 2016 International Congress

    Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2

    T. Hatano, A. Okuzumi, K. Kamagata, K. Daida, D. Taniguchi, M. Hori, H. Yoshino, S. Aoki, N. Hattori (Tokyo, Japan)

    Objective: Using neuromelanin (NM)-MRI, we analyzed whether disease severity and MF is associated with the degree of dopaminergic neuronal degeneration in the substantial nigra compacta…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley